Recommended Topic Related To:

Dopar

"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...

Dopar

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Warnings
Precautions

WARNINGS

Larodopa should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease.

Care should be exercised in administering Larodopa to patients with a history of myocardial infarction who have residual atrial, nodal or ventricular arrhythmias. If Larodopa is necessary in this type of patient, it should be used in a facility with a coronary care unit or an intensive care unit.

One must be on the alert for the possibility of upper gastrointestinal hemorrhage in those patients with a past history of active peptic ulcer disease.

All patients should be carefully observed for the development of depression with concomitant suicidal tendencies. Psychotic patients should be treated with caution.

Pyridoxine hydrochloride (vitamin B6) in oral doses of 10 mg to 25 mg rapidly reverses the toxic and therapeutic effects of Larodopa. This should be considered before recommending vitamin preparations containing pyridoxine hydrochloride (vitamin B6).

PRECAUTIONS

Periodic evaluations of hepatic, hematopoietic, cardiovascular and renal function are recommended during extended therapy in all patients.

Patients with chronic wide angle glaucoma may be treated cautiously with Larodopa, provided the intraocular pressure is well controlled and the patient monitored carefully for changes in intraocular pressure during therapy.

Postural hypotensive episodes have been reported as adverse reactions. Therefore, Larodopa should be administered cautiously to patients on antihypertensive drug (for patients receiving pargyline, see note on MAO inhibitors contraindications), and it may be necessary to adjust the dosage of the antihypertensive drugs.

Pregnancy Use

The safety of Larodopa in women who are or who may become pregnant has not been established; hence it should be given only when the potential benefits have been weighed against possible hazards to mother and child. Studies in rodents have shown that levodopa at dosages in excess of 200 mg/kg/day has an adverse effect on fetal and postnatal growth and viability

Larodopa should not be used in nursing mothers.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Warnings
Precautions
A A A

Additional Dopar Information

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.